IP Library Granted Patent US 9,062,059
Granted Patent B2
US 9,062,059 · App. 14/239,603 · Granted Jun 23, 2015

Pyrimidine PDE10 inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,062,059
App. No.
14/239,603
Granted
Jun 23, 2015
Kind
B2
Abstract

The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Claims (59)

1. A compound selected from the group consisting of

2-Methyl-6-{2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine,

2-Methyl-6-{[(1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine,

S,S-2-methyl-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]-6-{[2-(1,5-naphthyridin-2-yl)cyclopropyl]methoxy}pyrimidin-4-amine,

6-{[(1S,2 S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-N-4-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine,

5-fluoro-6-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-N-4-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidine-2,4-diamine,

6-{[2-(3,3′-bipyridin-6-yl)cyclopropyl]methoxy}-2-methyl-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine,

6-{[2-(5-cyclopropylpyridin-2-yl)cyclopropyl]methoxy}-2-methyl-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine, and

2-amino-4-{[(1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}-6-{[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]amino}pyrimidine-5-carbonitrile, or a pharmaceutically acceptable salt thereof.

2. A compound of structural formula:

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2 which is.

4. The compound according to claim 2 which is

in the form of a pharmaceutically acceptable salt.

5. A compound which is

or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 5 which is

7. The compound according to claim 5 which is

in the form of a pharmaceutically acceptable salt.

8. A compound which is

or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 8 which is

10. The compound according to claim 8 which is

in the form of a pharmaceutically acceptable salt.

11. A compound which is

or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 11 which is

13. The compound according to claim 11 which is

in the form of a pharmaceutically acceptable salt.

14. A compound which is

or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 14 which is

16. The compound according to claim 14 which is

in the form of a pharmaceutically acceptable salt.

17. A compound which is

or a pharmaceutically acceptable salt thereof.

18. The compound according to claim 17 which is

19. The compound according to claim 17 which is

in the form of a pharmaceutically acceptable salt.

20. A compound which is

or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 20 which is

22. The compound according to claim 20 which is

in the form of a pharmaceutically acceptable salt.

23. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound of claim 3 .

25. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound according to claim 4 .

26. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound of claim 6 .

27. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound according to claim 7 .

28. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound of claim 9 .

29. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound according to claim 10 .

30. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound of claim 12 .

31. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound according to claim 13 .

32. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound of claim 15 .

33. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound according to claim 16 .

34. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound of claim 18 .

35. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound according to claim 19 .

36. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound of 21.

37. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound according to claim 22 .

Assignments (1)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →